News
EVO
7.15
-1.24%
-0.09
Evotec and Variant Bio collaborate for fibrosis treatment
Evotec and Variant Bio collaborate for fibrosis treatment. The stock price dropped 2.5% on Thursday during pre-market hours of trading. Evotec SE and Variant bio entered a collaboration agreement to identify a best-in-class treatment for diseases caused by fibrosis.
Seeking Alpha · 12h ago
Evotec, Variant Bio Announce Collaboration Agreement To Identify Treatment For Diseases Caused By Fibrosis.
Benzinga · 13h ago
EVOTEC SE - COMMERCIAL TERMS INCLUDE RESEARCH FUNDING AND MILESTONES AND/OR ROYALTY PAYMENTS TO EVOTEC BASED ON OVERALL SUCCESS OF PROGRAM
Reuters · 13h ago
Weekly Report: what happened at EVO last week (0408-0412)?
Weekly Report · 3d ago
UPDATE 2-Europe's STOXX 600 flat on rising Middle East tensions, energy stocks spike
Europe's STOXX 600 flat on rising Middle East tensions, energy stocks spike. Main energy stocks index hits highest since 2008 in early trade. The pan-European index hits one-week high but closes 0.1% higher. Luxury giants LVMH and Richemont fall on ex-dividend trade.
Reuters · 6d ago
UPDATE 1-STOXX 600 climbs over 1% on rate-cut optimism
European shares rise to over a week's high after ECB hints at interest rate cuts as soon as June. Pan-European STOXX 600 gains 1.1% to a five-month high. Basic resources index leads sectoral gains. Varta slumps as its restructuring plans would fail to make it profitable by 2022.
Reuters · 6d ago
T. Rowe Price Raises Stake in Evotec SE
TipRanks · 04/08 14:27
Weekly Report: what happened at EVO last week (0401-0405)?
Weekly Report · 04/08 09:07
Weekly Report: what happened at EVO last week (0325-0329)?
Weekly Report · 04/01 09:07
Weekly Report: what happened at EVO last week (0318-0322)?
Weekly Report · 03/25 09:07
Weekly Report: what happened at EVO last week (0311-0315)?
Weekly Report · 03/18 09:07
Evotec AG’s Strategic Growth and Innovative R&D Poised for Market Success
TD Cowen analyst Steven Mah maintained a Buy rating on Evotec AG (EVO – Research Report) and set a price target of $21.00 for the company. Mah projects that Evotic will surpass €1 billion in revenues by 2025. The company is a leader in drug discovery and development.
TipRanks · 03/18 04:15
Weekly Report: what happened at EVO last week (0304-0308)?
Weekly Report · 03/11 09:07
Evotec And Claris Ventures Streamline Access To Accelerate Programmes From Claris's Portfolio Companies Into The Clinic
Benzinga · 03/06 08:12
Weekly Report: what happened at EVO last week (0226-0301)?
Weekly Report · 03/04 09:07
Weekly Report: what happened at EVO last week (0219-0223)?
Weekly Report · 02/26 09:08
Evolution And Caesars Digital Sign Strategic Agreement To Expand Partnership Throughout North America; Will Work Together To Establish Dedicated Studios Across Multiple U.S. States, Including One Inside Caesars' New Jersey-Based Tropicana Casino
Evolution and Caesars Digital will establish dedicated studios across multiple U.S. States. New Jersey-based Tropicana Casino will mark Evolution's third live casino studio in Atlantic City. Evolution will continue to offer live casino games and top-performing online slots.
Benzinga · 02/21 14:27
Weekly Report: what happened at EVO last week (0212-0216)?
Weekly Report · 02/19 09:08
Weekly Report: what happened at EVO last week (0205-0209)?
Weekly Report · 02/12 09:08
Evotec Subsidiary Just - Evotec Biologics Expands Development and Manufacturing Agreement with ABL for Broadly Neutralising Antibodies Against HIV, Financial Terms Undisclosed
Just - Evotec Biologics has expanded its relationship with Advanced BioScience Laboratories. The two companies will work together to develop and test antibodies against HIV. The expansion is funded by the US Government and biopharmaceutical industry. The company will develop a third bNAb against HIV for a Phase I clinical study.
Benzinga · 02/07 07:03
More
Webull provides a variety of real-time EVO stock news. You can receive the latest news about Evotec Ag through multiple platforms. This information may help you make smarter investment decisions.
About EVO
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.